Eagle IP is excited to announce that Jennifer Che, President and Managing Director, will be attending the BIO 2025 International Conference, taking place from June 16-19 at the Boston Convention and Exhibition Centre. Jennifer will be participating in some events together with Hong Kong’s Science and Technology Park (HKSTP), who is hosting the Hong Kong Pavilion at BIO, sending a large delegation of attendees, as well as organizing several events.

This premier biotechnology event attracts over 17,000 professionals from around the globe, featuring networking opportunities, educational sessions, and an exhibition hall showcasing the latest innovations in the industry. Jennifer is looking forward to engaging with fellow attendees and exploring potential collaborations. She invites anyone attending the conference to reach out for a meeting to discuss opportunities, exchange ideas, or simply connect.

About BIO 2025
The BIO International Convention is the world’s largest biotechnology event, providing a platform for networking, learning, and collaboration. Attendees can participate in sessions covering the latest trends, regulatory updates, and scientific advancements, making it an invaluable experience for professionals in the biotech sector.

About Eagle IP
EAGLE IP is a specialized patent firm based in Greater China that facilitates the transfer of new technology from the research environment into the marketplace. Our team of Chinese and US patent practitioners possesses strong cross-border IP knowledge, industry experience, and deep technical expertise. We specialize in China patent strategy, patent drafting and prosecution, patent invalidations, cross-border IP issues, global patent portfolio strategy & management, and Hong Kong patent matters. Our management system is ISO 9001 certified for excellent quality control and management. Should you have any questions, please feel free to contact us at [email protected]

If you won’t be able to attend BIO 2025 but will be in Boston and would like to schedule a meeting, please let us know.

We are looking forward to seeing you in Boston!

我們過去活動

Recommended Insights

AI, Big Data, and Blockchain - CNIPA seeks public comment on draft patent examination guidelines

2019年11月21日
Exciting new changes continue to happen with the Chinese Patent Office (CNIPA). On November 12, 2019, the CNIPA published a new set of amendments to Part II Chapter 9 of the Patent Examination Guidelines (“Draft”) and requested public comment by December 11, 2019. In summary, the new guidelines clarify how emerging technologies involving artificial intelligence, […]

New Policies to Promote Importation of Innovative Drugs

2018年11月8日
At the April 12, 2018 executive meeting of the State Council in China, Premier Mr. Li Keqiang indicated the government’s desire to increase China’s access to innovative drugs. To achieve this, the government would encourage importation of innovative drugs into China by streamlining the regulatory pathway, enhancing IP protection, and lowering the cost of medicine. […]

How to Protect a Crystal Form (Polymorph) Patent in China

2025年6月4日
Crystalline forms are critical to pharmaceutical patents, offering extended protection for improved stability, bioavailability, or manufacturability. However, securing such patents in China has grown increasingly difficult due to the China National Intellectual Property Administration (CNIPA)’s strict patentability criteria. Unlike the U.S. or Europe, where structural novelty or problem-solving utility may suffice, China demands quantifiable evidence of […]

A Detailed Dive into China’s New Patent Term Extension Provisions

2020年12月11日
This article is a part of a larger article that highlights the newest draft implementation rules of the new Chinese Patent Law. This particular article takes a detailed dive into the patent term extension/adjustment provisions. One of the biggest and most exciting provisions in the newly amended patent law is patent term extension for delay […]
Top crossarrow-right